Response Genetics (Response Genetics) Long-Term Debt : $10.76 Mil (As of Mar. 2015)

View and export this data going back to 2007. Start your Free Trial

What is Response Genetics Long-Term Debt?

Response Genetics's Long-Term Debt for the quarter that ended in Mar. 2015 was $10.76 Mil.

Response Genetics's quarterly Long-Term Debt declined from Sep. 2014 ($9.44 Mil) to Dec. 2014 ($6.56 Mil) but then increased from Dec. 2014 ($6.56 Mil) to Mar. 2015 ($10.76 Mil).

Response Genetics's annual Long-Term Debt increased from Dec. 2013 ($1.00 Mil) to Dec. 2014 ($6.56 Mil) but then declined from Dec. 2014 ($6.56 Mil) to Dec. 2015 ($4.64 Mil).

Response Genetics Long-Term Debt Historical Data

The historical data trend for Response Genetics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Response Genetics Long-Term Debt Chart

Response Genetics Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Long-Term Debt

Get a 7-Day Free Trial

1.00

6.56

4.64

Response Genetics Quarterly Data
	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Dec15
Long-Term Debt	Get a 7-Day Free Trial															1.50	9.44	6.56	10.76	4.64

Response Genetics (OTCPK:RGDXQ) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Response Genetics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Response Genetics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Response Genetics (Response Genetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Response Genetics Inc (OTCPK:RGDXQ) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070

Website

http://www.responsegenetics.com

Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.

Executives

Roberto Mignone	10 percent owner	C/O BRIDGER MANAGEMENT, LLC., 90 PARK AVENUE, 40TH FL., NEW YORK NY 10016
Bridger Management Llc	10 percent owner	90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Swiftcurrent Offshore Ltd	10 percent owner	C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104
David Schreiber	director	15 TROTTERS LANE, MONROE CT 06468
Sam Chawla	director	1640 MARENGO STREET, 6TH FLOOR, LOS ANGELES CA 90033
Van Den Broek Richard	director	73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Kevin Roy Harris	officer: Vice President and CFO	345 N MAPLE DRIVE, SUITE 120, BEVERLY HILLS CA 90210
Kirk K Calhoun	director	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael Serruya	director	C/O RESPONSE GENETICS, INC., 1640 MARENGO ST., 6TH FLOOR, LOS ANGELES CA 90033
Thomas A Bologna	director, officer: Chief Executive Officer	4390 US ROUTE ONE, PRINCETON NJ 08540
Marxe Austin W & Greenhouse David M	10 percent owner	C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Partners Swiftcurrent	10 percent owner	90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Bridger Capital Llc	10 percent owner	90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Plc Glaxosmithkline	10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Michael A Metzger	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451

Response Genetics (Response Genetics) Headlines

From GuruFocus

Response Genetics Inc. (RGDX) CFO Thomas Stankovich buys 7,000 Shares

By GuruFocus Research GuruFocus Editor • 12-14-2009

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-14-2010

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus • 05-15-2009

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-09-2010

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 08-22-2009

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-16-2009